Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

Clinical trial NCT03347292 · COMPLETED

Trial details

NCT number: NCT03347292
Sponsor: Bayer
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Carcinoma, Hepatocellular

Start date: 2018-06-18
Primary completion: 2020-12-17
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.